Physician profile
David B Cahn
NPI 1154683829
$31,547.19
in general payments reported to CMS, 2019-2025
42 companies · $21K in 2025
The $21K reported for 2025 was more than what 96% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,077 · 2020: $759 · 2021: $759 · 2022: $1,639 · 2023: $1,674 · 2024: $5,057 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $20K · Food and Beverage: $7,206 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $19,601.37 |
| Food and Beverage | $7,206.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $505.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $8,359.04 | 2025 | |
| Pfizer INC. | $7,904.16 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $4,529.97 | 2022-2025 | Erleada |
| Dendreon Pharmaceuticals LLC | $1,138.07 | 2019-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $1,118.56 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $839.12 | 2019-2025 | |
| Janssen Biotech, INC. | $832.62 | 2019-2025 | Erleada, Akeega, Balversa |
| Astellas Pharma US INC | $711.79 | 2019-2025 | Xtandi, Myrbetriq, Veozah |
| Ferring Pharmaceuticals INC. | $688.70 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $611.43 | 2021-2025 | Lupron Depot, Botox |
| Sumitomo Pharma America, INC. | $518.14 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $516.01 | 2021-2025 | Urolift, Barrigel |
| Merck Sharp & Dohme LLC | $453.08 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Axonics, INC. | $449.41 | 2022-2024 | Axonics |
| Immunitybio, INC. | $347.00 | 2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $333.62 | 2023-2025 | Eligard, Jatenzo |
| Boston Scientific Corporation | $296.27 | 2019-2024 | Rezum Generator |
| Urogen Pharma, INC. | $293.59 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $256.67 | 2020-2023 | Prolaris, Myrisk |
| Astrazeneca Pharmaceuticals LP | $215.76 | 2022-2025 | Lynparza |
| Telix Pharmaceuticals | $146.21 | 2023-2025 | Illuccix |
| Verity Pharmaceuticals INC. | $130.88 | 2022-2025 | Trelstar |
| Intuitive Surgical, INC. | $128.13 | 2019 | |
| Neotract INC. | $99.23 | 2019 | |
| Progenics Pharmaceuticals, INC. | $89.28 | 2023-2025 | Pylarify |
| Blue Earth Diagnostics | $73.07 | 2020-2022 | |
| Tolmar Pharmaceuticals, INC. | $61.50 | 2021-2022 | |
| Amgen INC. | $57.39 | 2020-2024 | Prolia |
| Myovant Sciences INC. | $52.14 | 2022 | |
| Dentsply Ih Ab | $37.07 | 2023 | Lofric |
| Ambu INC. | $34.75 | 2024 | |
| Clinigen, INC. | $31.15 | 2019-2020 | |
| Coloplast Corp | $30.91 | 2022 | |
| Allergan, INC. | $23.79 | 2021 | |
| Clarus Therapeutics INC. | $23.71 | 2021 | |
| Accord Healthcare, INC. | $21.82 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $20.96 | 2022 | |
| Procept Biorobotics Corporation | $17.17 | 2024 | Aquabeam System |
| Baxter Healthcare | $16.23 | 2021 | |
| Dentsply Ih INC. | $14.92 | 2022 | |
| Foundation Medicine, INC. | $12.30 | 2020 | |
| Urovant Sciences INC | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.